Cabazitaxel-d9 (Synonyms: XRP6258-d9; RPR-116258A-d9; taxoid XRP6258-d9) |
| カタログ番号GC45395 |
カバジタキセル-d9 は重水素標識カバジタキセルです。カバジタキセルは、潜在的な抗腫瘍活性を持つ天然タキソイド 10-デアセチルバッカチン III の半合成誘導体です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1383572-19-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cabazitaxel-d9 is intended for use as an internal standard for the quantification of cabazitaxel by GC- or LC-MS. Cabazitaxel is a second generation semisynthetic taxane derived from 10-deacetylbaccatin III .1 It stabilizes microtubule assembly by reducing lag time for tubulin assembly (LT50 = 100 nM) and the rate of cold-induced microtubule depolymerization (IC50s = 100-250 nM) in vitro. Cabazitaxel inhibits proliferation of P388, HL-60, Calc18, and KB cells (IC50s = 4-41 nM), as well as P-glycoprotein-expressing, drug-resistant versions of these cell lines (IC50s = 16-414 nM). In vivo, cabazitaxel dose-dependently reduces tumor growth in docetaxel-susceptible N87 human gastric carcinoma and docetaxel-resistant UISO BCA-1 breast cancer mouse xenograft models. Formulations containing cabazitaxel have been used in combination with prednisone in the treatment of hormone-refractory metastatic prostate cancer.
References
1. Vrignaud, P., SÉmiond, D., Lejeune, P., et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin. Cancer Res. 19(11), 2973-2983 (2013).
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *